Study of Vorasidenib in severe liver disease and healthy volunteers
Treatments studied
This trial tests how the drug vorasidenib behaves in people with severe liver problems compared to healthy volunteers. It helps doctors understand if the drug needs different dosing for patients with liver disease.
Summary written for real people, not researchers, by Clin2.
Who can take part
- For liver disease group: You must have cirrhosis with severe liver impairment (Child-Pugh score 10–15) and be medically stable for at least 1 month.
- For liver disease group: You cannot have had worsening of hepatic encephalopathy (confusion from liver issues) in the past 6 months.
- For healthy volunteer group: You must have normal liver function and match a liver disease participant by age, sex, race, weight, and smoking habits.
- For both groups: You cannot be pregnant, breastfeeding, or planning pregnancy within 90 days of taking the drug.
- For both groups: You must avoid grapefruit, alcohol, caffeine, and certain other foods/beverages before and during the study.
- For both groups: You cannot have had cancer (except some skin cancers) in the last 5 years.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests how a drug (BMS-986435) behaves in people with normal liver function versus those with liver problems. It also checks that the drug is safe for the heart.
This research study tests how two experimental drugs (AZD9550 and AZD6234) work in people with different levels of liver function. The goal is to understand whether liver disease changes how the body processes these medications, which may help doctors safely treat patients with liver problems in the future.
This study tests a new medicine called AZD4144 to see how the body handles it in people with different levels of liver function. It may help doctors understand how to dose the medicine for people with liver disease.
This Phase 1 study tests how two investigational medicines move through the body and how safe they are in people with different levels of liver impairment, compared with healthy volunteers. It may help doctors understand dosing and safety for people with liver problems.
This trial tests how the drug capivasertib is processed by the body and how safe it is in people with moderate liver impairment. It aims to find the right dose for patients whose liver function is reduced but stable.
This trial tests whether taking vorasidenib after standard radiation and chemotherapy can help prevent low-grade IDH-mutant astrocytoma from growing back. It is for people who have completed first-line therapy and whose tumors have not progressed.
Hear when a new Severe Hepatic Impairment trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.